Acute lymphoblastic leukemia (ALL) is considered as the most common malignant neoplasm of childhood and the frequent cause of death from cancer before 20-years of age. The facial swelling mimicking a maxillofacial tumor is rarely associated with ALL. Clinicians should be aware of such rare manifestation of ALL. We present a case with an atypical mass in the facial region secondary to ALL, which resulted in diagnostic dilemma. Reports of such atypical swelling in patients with ALL are occasional. The swelling was aggressive and the disease had a fulminant course.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.22514/jocpd.2022.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in the role of atypical cadherin FAT1 in tumorigenesis (Review).
Oncol Lett
March 2025
Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong 257000, P.R. China.
The FAT atypical cadherin 1 (FAT1) gene is the ortholog of the fat gene and encodes the protocadherin FAT1. FAT1 belongs to the cadherin superfamily, a group of full-length membrane proteins that contain cadherin-like repeats. In various types of human cancer, FAT1 is one of the most commonly mutated genes, and is considered to be an emerging cancer biomarker and a potential target for novel therapies.
View Article and Find Full Text PDFDisseminated Intravascular Coagulation in Pediatric Acute Leukemia: Prevalence, Laboratory Features, and Prognostic Significance of ISTH Score.
Int J Lab Hematol
January 2025
Department of Hematology and Coagulation, Princess Iman Center for Research and Laboratory Sciences, Amman, Jordan.
Introduction: Disseminated intravascular coagulation (DIC) is associated with acute leukemia. DIC prevalence and clinical consequences are complex and varies across acute leukemia subtypes. The International Society of Thrombosis and Hemostasis (ISTH) scoring system is used for the detection of overt DIC.
View Article and Find Full Text PDFPsychiatric Disorders in Survivors of Pediatric Acute Lymphoblastic Leukemia in India.
Indian J Pediatr
January 2025
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Objectives: To determine the prevalence of psychiatric morbidities in survivors of pediatric acute lymphoblastic leukemia (ALL) and to identify any risk factors.
Methods: Survivors of ALL, who had completed their treatment, atleast two or more years ago and now were 6-18 y old were enrolled on the study. The Mini International Neuropsychiatric Interview (M.
Orchard: Building large cancer phylogenies using stochastic combinatorial search.
PLoS Comput Biol
December 2024
Computational and Systems Biology Program, Sloan Kettering Institute, New York, New York, United States of America.
Phylogenies depicting the evolutionary history of genetically heterogeneous subpopulations of cells from the same cancer, i.e., cancer phylogenies, offer valuable insights about cancer development and guide treatment strategies.
View Article and Find Full Text PDFPEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia.
Ann Hematol
January 2025
Department of Hematology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, 107 West Culture Road, Lixia District, Jinan, 250012, P.R. China.
To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) and rhG-CSF in the recovery of neutrophils after induction therapy in ALL patients, PEG-rhG-CSF was injected subcutaneously within 24 ~ 48 h after the end of intravenous infusion of daunorubicin/idarubicin during induction chemotherapy. In rhG-CSF group, patients were given rhG-CSF. The main outcome indexes were the incidence and duration of grade 4 chemotherapy-induced-neutropenia (CIN, ANC less than 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!